Home > Result Summaries: Compounds > Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine Result Summaries: Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine GSKStudy ID Phase Title Summary (Download) 103532 phase 2 Assess the immunogenicity, safety, reactogenicity of 1 dose of 4 different formulations of GSK Biologicals’ meningococcal conjugate vaccine (MenACWY) vs 1 dose of Mencevax™ ACWY in healthy subjects aged 15-19 yrs (0 citation(s)) 103533 phase 2 Evaluate the immunogenicity, reactogenicity, safety of 4 different formulations of GSK Biologicals' conjugate vaccine (MenACWY) vs 1 dose of MenC-CRM197 or Mencevax™ ACWY in children aged 12-14 m & 3-5 y (0 citation(s)) 104702 phase 2 A primary vaccination study to assess the immunogenicity,safety & reactogenicity of 1 dose of 4 different formulations of GSK Biologicals’ meningococcal conjugate vaccine (MenACWY) vs 1 dose of MENCEVAX™ ACWY in healthy subjects aged 15-19 yrs (2 citation(s)) 104703 (Primary study) phase 2 A Phase II, open (partially double-blind), randomized, controlled dose-range study to evaluate the immunogenicity, reactogenicity and safety of investigational vaccination regimens versus MENINGITEC™ or MENCEVAX™ ACWY when given as one dose to children aged 12 to 14 months and 3 to 5 years old (5 citation(s)) 107137_ phase 3 Prophylactic antipyretic treatment in children receiving booster dose of pneumococcal vaccine GSK1024850A and DTPa-HBV-IPV/Hib vaccine (Infanrix hexa) and assessment of impact of pneumococcal vaccination on nasopharyngeal carriage (6 citation(s)) 107386 phase 2 Phase IIb Primary Vaccination Study to Evaluate Non-Inferiority & Persistence of the Immune Response of GSK Biologicals' MenACWY Conjugate Vaccine (Intramuscularly) vs Mencevax ACWY (Subcutaneously) to Healthy Subjects (11-55 Years of Age) (2 citation(s)) 107408 phase 2 Immunogenicity & safety study of GSK Biologicals’ meningococcal vaccine GSK134612 administered in healthy subjects either previously primed with Mencevax™ ACWY or naïve to meningococcal vaccination. (2 citation(s)) 108595 Mth18 phase 2 Assess long term persistence of a primary dose of GSK Biologicals' meningococcal vaccine 134612 versus one dose of Mencevax™ ACWY in healthy adolescents/young adults (15 to 19 years at vaccination) (1 citation(s)) 108658 phase 2 Evaluate Non-Inferiority and Persistence of the Immune Response of GSK Biologicals' Meningococcal Vaccine 134612 Versus Meningitec™ or Mencevax™ ACWY in Healthy Subjects (1-10 Years of Age) (7 citation(s)) 109063 phase 3 Non-inferiority of GSK Biologicals’ meningococcal vaccine 134612 given concomitantly with GSK Biologicals’ Twinrix™ versus 134612 alone and Twinrix™ alone in healthy subjects aged 11 through 17 years. (2 citation(s)) 109067 phase 3 Lot-to-Lot Consistency, Non-Inferiority Versus Mencevax™ and Evaluation of the co-Administration With Fluarix™ of GSK Biologicals' Meningococcal Vaccine GSK134612, in Healthy Subjects Aged 18 Through 55 Years of Age (3 citation(s)) 109069 phase 3 Primary Vaccination Study in Subjects Aged 11-17 Years to Demonstrate the Non-Inferiority of GSK Biologicals' Meningococcal Vaccine GSK134612 Vaccine Versus Mencevax™ ACWY (1 citation(s)) 109375 phase 2 Study to assess immunogenicity, reactogenicity and safety of primary vaccination with GSK Biologicals' MenACWY vaccine (GSK134612) given as 1 or 2 doses to healthy toddlers 9-12 months of age (1 citation(s)) 109377 phase 2 Study to Assess Immunogenicity, Reactogenicity and Safety of 1 Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 vs. 1 Dose of Sanofi-Pasteur's Menactra® in Healthy Subjects 10-25 Years. (2 citation(s)) 109495 phase 3 Non-Inferiority of GSK Biologicals' Meningococcal Vaccine GSK134612 Versus Mencevax™ in Healthy Subjects Aged 2 Through 10 Years of Age (1 citation(s)) 109670 phase 3 Immunogenicity & Safety Study of GSK Biologicals' Meningococcal Vaccine GSK134612 When co-Administered With GSK Biologicals' MMRV Vaccine (Priorix-Tetra™) in Healthy 12 to 23-Month-Old Children (3 citation(s)) 109835 phase 3 Co-Administration of GSK Biologicals' Meningococcal Vaccine GSK134612 With Infanrix hexa™, Compared to Individual Administration of Each Vaccine, in Healthy 12- Through 23-Month-Old Children (2 citation(s)) 110870 phase 3 Immunogenicity & safety study of a booster dose of an investigational vaccination regimen given at 12-15 months of age or at 15-18 months of age (co-administered with Infanrix®) in primed healthy toddlers (0 citation(s)) 111393 phase 3 Immunogenicity & safety study of GSK Biologicals’ meningococcal vaccine GSK134612 when co-administered with GSK Biologicals’ pneumococcal vaccine GSK1024850A in healthy 12-23-month-old children previously primed with GSK1024850A (2 citation(s)) 111414 phase 3 Non-inferiority of GSK Biologicals’ meningococcal vaccine (GSK134612) compared to licensed MenC-CRM197 conjugate vaccine in healthy children (2 citation(s)) 111670 phase 2 Long-term antibody persistence of GSK Biologicals' meningococcal vaccine GSK134612 versus Menactra® in healthy adolescents/adults aged 10-25 years and booster response to vaccine GSK134612 administered at 5 years post-primary vaccination (1 citation(s)) 112021 phase 2 The long term antibody persistence study of GSK Biologicals’ meningococcal vaccine GSK 134612 administered as 1 or 2 doses to healthy toddlers at 9-12 months of age and as a booster dose at 5 years post-primary vaccination (1 citation(s)) 112036 phase 3 Persistence of antibodies after GSK Biologicals’ meningococcal vaccine GSK134612 in toddlers (1 citation(s)) 112148 phase 3 Persistence of antibodies after vaccination with GSK Biologicals’ meningococcal vaccine GSK134612 in adolescents and young adults (1 citation(s)) 113807 phase 3 Phase IIIb immunogenicity, safety and reactogenicity study of GSK Biologicals’ meningococcal vaccine [GSK 134612] when given as one dose to healthy subjects aged 56 years or older (1 citation(s)) 113977 phase 3 Persistence of antibodies after vaccination with a dose of GSK Biologicals’ meningococcal vaccine GSK134612 in healthy children and safety and immunogenicity of a booster dose at 68 months post-primary vaccination (0 citation(s)) 114248 phase 3 Immunogenicity and safety study of one dose of GSK Biologicals’ meningococcal vaccine GSK 134612 (blinded lots) versus one dose of Mencevax™ ACWY in healthy subjects aged 18-25 years (0 citation(s)) 114249 phase 2 Immunogenicity and safety study of one dose of GSK Biologicals’ meningococcal vaccine GSK 134612 (blinded lots) versus one dose of Menactra® in healthy subjects aged 10-25 years (1 citation(s)) 134612/003 phase 2 Assess the safety, reactogenicity, immunogenicity & long-term persistence of one intramuscular dose of GSK Biologicals' MenACWY conjugate vaccine vs one subcutaneous dose of Mencevax™ ACWY in healthy adults aged 18-25 yrs (1 citation(s)) 134612/004 phase 2 A Phase II, open (partially double-blind), randomized, controlled dose-range study to evaluate the immunogenicity, reactogenicity and safety of investigational vaccination regimens versus a licensed MenC vaccine or Mencevax™ ACWY when given in children aged 12 to 14 months and 3 to 5 years old (0 citation(s)) 134612/005 phase 2 A Phase II, open (partially double-blind), randomized, controlled dose-range study to evaluate the immunogenicity, reactogenicity and safety of investigational vaccination regimens versus Mencevax ACWY when given in children aged 3 to 5 years old (0 citation(s))
